Women's Health

Stubborn politicians get flooded by women's health facts via fax

Stubborn politicians get flooded by women's health facts via fax

By

How Huge and the New York Civil Liberties Union used lawmakers' own antiquated ideas to support the Reproductive Health Act.

CDM New York's Carolyn O'Neill on 'femvertising'

CDM New York's Carolyn O'Neill on 'femvertising'

"Other brands have missed the mark, with an apparent belief that once you hashtag it, they will come," she writes.

Mother New York fills resume gaps with 'The Pregnancy Pause'

Mother New York fills resume gaps with 'The Pregnancy Pause'

By

For Mother's Day, the agency gives job-hunters a way to proudly display maternity leave as a full-time job.

Five things for pharma marketers to know: Monday, May 1, 2017

Five things for pharma marketers to know: Monday, May 1, 2017

By

The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage

Five things for pharma marketers to know: Monday, April 17, 2017

Five things for pharma marketers to know: Monday, April 17, 2017

By

Kardashian West promotes Diclegis again; drugmakers are developing non-opioid painkillers; healthcare brands test Facebook Live

Dr. Mylene Yao, Univfy

Dr. Mylene Yao, Univfy

Dr. Mylene Yao is co-founder and CEO of Univfy.

How Duchesnay USA got over the Kardashian marketing bump

How Duchesnay USA got over the Kardashian marketing bump

By

The drugmaker still views Instagram as a viable marketing platform, however.

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

By

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.

U by Kotex opens up a period-themed pop-up shop

U by Kotex opens up a period-themed pop-up shop

By

"The Period Shop" is the first effort in a multi-year "Period Projects" campaign.

Medicines360 CEO battles for IUD access

Medicines360 CEO battles for IUD access

By

Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.

The FDA approves sex-drive pill, Addyi

The FDA approves sex-drive pill, Addyi

By

Sprout plans to hire 200 sales reps, targeting 30,000 doctors, to accompany the drug's launch.

Bad ad watchdog slams Kardashian's social-media post

Bad ad watchdog slams Kardashian's social-media post

By

The FDA said Kim Kardashian West's promotion of morning-sickness pill Diclegis misbranded the product by understating its risks.

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

By

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Five things for pharma marketers to know: Thursday, May 7

Five things for pharma marketers to know: Thursday, May 7

By

A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

By

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

Physicians call for emphasis on women's health research and care

Physicians call for emphasis on women's health research and care

By

Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.

Study shows impact of the "Angelina Jolie effect"

Study shows impact of the "Angelina Jolie effect"

By

AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.

Pfizer Ibrance is first approved CDK inhibitor

Pfizer Ibrance is first approved CDK inhibitor

By

The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.

Pfizer cancer drug skips FDA advisory panel

Pfizer cancer drug skips FDA advisory panel

By

The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.

Pfizer brings humor to menopause marketing

Pfizer brings humor to menopause marketing

The new approach shows "The Talk" has a sequel.

Merck rolls out new Keytruda data in hard-to-treat group

Merck rolls out new Keytruda data in hard-to-treat group

By

The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.

Five things for pharma marketers to know: Wednesday, December 3

Five things for pharma marketers to know: Wednesday, December 3

By By

An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.

Insurer's maternity app rewards healthy behaviors

Insurer's maternity app rewards healthy behaviors

By

United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.

Coalition urges gender-specific heart research

Coalition urges gender-specific heart research

By

The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.

Pfizer gets palbo review date

Pfizer gets palbo review date

By

The FDA will vote for or against the breast cancer drug by April 13, 2015.

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

By

The drugmaker is poised to cut 14 pipeline projects loose.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.

FDA tackles women's sexual health

The regulator and patients will chat for two days in October.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.